Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non-Current Assets: 2009-2024

Historic Non-Current Assets for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to $168.5 million.

  • Ironwood Pharmaceuticals' Non-Current Assets fell 42.05% to $122.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $122.2 million, marking a year-over-year decrease of 42.05%. This contributed to the annual value of $168.5 million for FY2024, which is 29.12% down from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Non-Current Assets of $168.5 million as of FY2024, which was down 29.12% from $237.8 million recorded in FY2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' Non-Current Assets peaked at $381.7 million during FY2021, and registered a low of $63.4 million during FY2020.
  • For the 3-year period, Ironwood Pharmaceuticals' Non-Current Assets averaged around $242.1 million, with its median value being $237.8 million (2023).
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Non-Current Assets slumped by 33.89% in 2020, and later surged by 502.06% in 2021.
  • Over the past 5 years, Ironwood Pharmaceuticals' Non-Current Assets (Yearly) stood at $63.4 million in 2020, then skyrocketed by 502.06% to $381.7 million in 2021, then dropped by 16.19% to $319.9 million in 2022, then decreased by 25.67% to $237.8 million in 2023, then decreased by 29.12% to $168.5 million in 2024.